10-K/A: Pharma-Bio Serv Amends Annual Report to Include Part III Information

Pharma-Bio Serv, Inc. has filed an amendment to its annual report on Form 10-K to include required information regarding directors, executive compensation, and other corporate governance matters.

Summary

• Pharma-Bio Serv, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended October 31, 2023.
• This amendment, designated as Form 10-K/A (Amendment No. 1), primarily includes information required by Items 10 through 14 of Part III of the original 2023 Form 10-K.
• The amendment also includes certifications required by the Sarbanes-Oxley Act of 2002 in Item 15 of Part IV.
• The original 2023 Form 10-K was filed on January 29, 2024, and this amendment speaks as of that original filing date.
• The company has not updated disclosures to reflect events after the original filing date, except as expressly indicated in this amendment.
• The amendment should be read in conjunction with the original 2023 Form 10-K and other SEC filings.
• The company's common stock outstanding as of January 24, 2024, was 22,963,143 shares.
• The aggregate market value of common stock held by non-affiliates on April 30, 2023, was $13,638,206.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, providing necessary information about the company's governance and compensation. There are no significant positive or negative surprises, hence a neutral to slightly positive sentiment.

Positives

• The company has a clearly defined corporate governance structure with independent directors on key committees.
• Executive compensation is transparent and detailed in the report.
• The company has established procedures for stockholder nominations to the board.
• The company has a code of ethics for senior management and directors.
• The audit committee pre-approves all audit and non-audit services provided by the independent auditors.

Negatives

• The company leases office space from a related party, which could present a conflict of interest.
• The company's stock is not traded on the Nasdaq market, despite using Nasdaq rules for director independence.
• The company's financial statements are included in the original 10-K filing, not this amendment.

Risks

• The related party lease agreement could pose a risk if not managed properly.
• The company's reliance on a single audit firm could pose a risk if the firm's independence is compromised.
• The company's compensation policies could be a risk if they incentivize excessive risk-taking.

Management Comments

• The company's board has determined that Mr. Spindel qualifies as an Audit Committee financial expert.
• The Compensation Committee has determined that no risks exist rising from the Company's compensation policies and practices for its employees that are reasonably likely to have a material adverse effect on the Company.

Industry Context

This filing is a standard annual report amendment, focusing on corporate governance and executive compensation, which is typical for publicly traded companies. The details provided are consistent with regulatory requirements for transparency and accountability.

Comparison to Industry Standards

• The compensation structure for executives and directors is comparable to other small to mid-sized public companies.
• The use of stock options as part of compensation is a common practice in the industry.
• The related party lease agreement is not uncommon but requires careful monitoring to ensure fair market value.
• The audit fees and services provided by Crowe are within the range of what is typical for a company of this size.

Related Party Transactions

• The company leases office facilities from an affiliate of a past Chairman of the Board and greater than 5% stockholder.

Stakeholder Impact

• Shareholders are provided with detailed information about the company's governance and compensation practices.
• Employees are informed about the compensation structure for executives.
• The related party lease agreement may be of interest to creditors and suppliers.

Key Dates

Keywords

corporate governance, executive compensation, directors, audit committee, financial reporting, stock options, related party transactions, Sarbanes-Oxley Act, independent directors, Form 10-K/A